5
MPS Pharmaa
531686 BSE
MPS Pharmaa
Healthcare BSE: 531686 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹3.80 Cr
P/E Ratio
-3.7
EBITDA
₹-0.95 Cr
Return on Equity
-83.08%
Debt to Equity
107.43
Book Value
₹0.04
52W High
₹2.08
52W Low
₹1.57
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
5- Stock is trading at 54.3 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 35.9%
- Company has a low return on equity of -61.4% over last 3 years.
- Company might be capitalizing the interest cost
Growth Rate
Revenue Growth
—
Net Income Growth
17.78% higher than
3Y
Cash Flow Change
9.52% lower than
3Y
ROE
96.83% higher than
3Y
ROCE
75.63% lower than
3Y
EBITDA Margin (Avg.)
-100% level than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.19 | 0.21 | 0.18 | 0.21 | 0.19 | 0.19 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.37 | 0.2 |
| Operating Profit | -0.19 | -0.21 | -0.18 | -0.21 | -0.19 | -0.19 | -0.18 | -0.19 | -0.19 | -0.19 | -0.19 | -0.37 | -0.2 |
| Other Income | 0.03 | 0.06 | 0 | 0 | 0 | 0 | 0.04 | 0 | 0 | 0 | 0 | 0.04 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| PBT | -0.2 | -0.19 | -0.22 | -0.25 | -0.23 | -0.23 | -0.18 | -0.23 | -0.23 | -0.23 | -0.23 | -0.37 | -0.24 |
| Tax % | -5% | -5.26% | -4.55% | 0% | -4.35% | -4.35% | 0% | 21.74% | -4.35% | -4.35% | -4.35% | -2.7% | 0% |
| Net Profit | -0.19 | -0.18 | -0.21 | -0.24 | -0.22 | -0.22 | -0.17 | -0.28 | -0.22 | -0.22 | -0.22 | -0.36 | -0.24 |
| EPS in Rs | -0.1 | -0.09 | -0.11 | -0.13 | -0.12 | -0.12 | -0.09 | -0.15 | -0.12 | -0.12 | -0.12 | -0.19 | -0.13 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0 | 0 | 0.03 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.8 | 0.77 | 0.95 | 0.95 |
| Operating Profit | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.8 | -0.77 | -0.95 | -0.95 |
| OPM % | 6.62% | -36.3% | -242.25% | -12.96% | -87.95% | — | — | -2266.67% | — | — | — | — | — |
| Other Income | 0 | 0 | 0.03 | 0.06 | 0.02 | 0.01 | 0.2 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 | 0.04 |
| Interest | 1.08 | 0.08 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.15 | 0.16 |
| PBT | -0.92 | -1.19 | -7.44 | -1.06 | -1.3 | -1.23 | -4.5 | -0.93 | -1.08 | -0.86 | -0.87 | -1.06 | -1.07 |
| Tax % | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | -3.77% | — |
| Net Profit | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.9 | -1.02 | -1.04 |
| EPS in Rs | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.53 | -0.56 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 4.17 | -0.13 | -7.5 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -19.04 |
| Borrowings | 7.78 | 6.65 | 2.9 | 2.9 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.52 |
| Other Liabilities | 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.7 | 0.8 | 0.89 |
| Total Liabilities | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.3 | 10.16 | 10.19 | 9.94 | 9.34 | 8.48 |
| Fixed Assets | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.66 |
| CWIP | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.9 | 3.42 | 3.4 | 3.26 | 2.91 | 2.41 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| Other Assets | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 1.87 |
| Total Assets | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.3 | 10.16 | 10.19 | 9.94 | 9.34 | 8.48 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 2.16 | 1.25 | 0.37 | -0.34 | 0.61 | -0.49 | -0.93 | -4.34 | -0.87 | -0.63 | -0.57 | -0.59 |
| Investing | -0.44 | -0.05 | 0.63 | 0.3 | -0.22 | 0.46 | 1.54 | 0.46 | -0.1 | 0.12 | 0.38 | 0.52 |
| Financing | -1.75 | -1.19 | -0.98 | 0 | -0.39 | 0.03 | -0.61 | 3.88 | 0.96 | 0.51 | 0.18 | 0.07 |
| Net Cash Flow | -0.03 | 0.01 | 0.02 | -0.04 | 0 | 0 | 0 | 0 | -0.01 | 0 | 0 | 0 |
| Free Cash Flow | 1.72 | 1.2 | 1 | -0.04 | 0.39 | -0.04 | 0.22 | -3.88 | -0.97 | -0.51 | -0.19 | -0.07 |
| CFO/OP | 267 | -292 | -5 | 64 | -84 | 73 | 22 | 638 | 92 | 79 | 74 | 62 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 229 | 1,154 | 532 | 344 | 1,148 | — | — | 365 | — | — | — | — |
| Inventory Days | 274 | 6,544 | 50.05 | 58.94 | 254 | — | — | 4,015 | 4,563 | — | — | — |
| Days Payable | 123 | 556 | 15.95 | 14.48 | 71.22 | — | — | 876 | 1,825 | — | — | — |
| Cash Conversion Cycle | 380 | 7,142 | 566 | 389 | 1,330 | — | — | 3,504 | — | — | — | — |
| Working Capital Days | 209 | 1,725 | -116 | -87.46 | -849 | — | — | -49,397 | — | — | — | — |
| ROCE % | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% | -13.14% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view MPS Pharmaa insights
65 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Confirmation On Non Applicability Of The Criteria Specified Under SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 Dated August 10, 2021 Read With The SEBI/HO/DDHS/DDHS- RACPOD1/P/CIR/2023/172 Dated October 19, 2023
19 Apr - MPS Pharmaa confirms it is not a Large Corporate as of 31 March 2026. 19 Apr - MPS Pharmaa confirms it is not a Large Corporate as of 31 March 2026.
2
Confirmation On Non Applicability Of The Criteria Specified Under SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 Dated August 10, 2021 Read With The SEBI/HO/DDHS/DDHS- RACPOD1/P/CIR/2023/172 Dated October 19, 2023
13h - MPS Pharmaa confirms it is not a Large Corporate as of 31 March 2026. 13h - MPS Pharmaa confirms it is not a Large Corporate as of 31 March 2026.
3
Statement Of Investor Complaints For The Quarter And Year Ended 31St March, 2026
13 Apr - Investor complaints statement for quarter ended 31 March 2026: nil received, disposed, or pending. 13 Apr - Investor complaints statement for quarter ended 31 March 2026: nil received, disposed, or pending.
4
Statement Of Investor Complaints For The Quarter And Year Ended 31St March, 2026
13 Apr - Quarter ended 31 March 2026 investor complaints statement shows nil complaints received, disposed, or pending. 13 Apr - Quarter ended 31 March 2026 investor complaints statement shows nil complaints received, disposed, or pending.
5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026. 13 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026.
Frequently Asked Questions about MPS Pharmaa
What does MPS Pharmaa Ltd do?
Incorporated in 1997, MPS Pharmaa Ltd manufactures and sells pharmaceutical
products[1]
Where is MPS Pharmaa Ltd (531686) listed?
MPS Pharmaa Ltd trades under code 531686 on the BSE.
Which sector does MPS Pharmaa Ltd belong to?
MPS Pharmaa Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of MPS Pharmaa Ltd?
MPS Pharmaa Ltd has a market capitalisation of ₹3.8 Cr, which places it in the Small Cap band.
What is the PE ratio of MPS Pharmaa Ltd?
MPS Pharmaa Ltd trades at a PE ratio of -3.70, against a book value of ₹0.04 per share.
What is the 52-week high and low of MPS Pharmaa Ltd?
Over the last 52 weeks MPS Pharmaa Ltd has traded between ₹1.57 and ₹2.08.
What is the Return on Equity (ROE) of MPS Pharmaa Ltd?
MPS Pharmaa Ltd reported a return on equity of -83.08%. Its debt-to-equity ratio is 107.43.
Company Information
Incorporated in 1997, MPS Pharmaa Ltd manufactures and sells pharmaceutical products[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531686.md for MPS Pharmaa Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.